Celyad Oncology SA (CYAD.BR)

EUR 0.47

(0.65%)

Total Liabilities Summary of Celyad Oncology SA

Celyad Oncology SA's latest annual total liabilities in 2023 was 9.97 Million EUR , down -35.2% from previous year.
Celyad Oncology SA's latest quarterly total liabilities in 2024 Q2 was 9.58 Million EUR , down 0.0% from previous quarter.
Celyad Oncology SA reported annual total liabilities of 15.39 Million EUR in 2022, down -57.58% from previous year.
Celyad Oncology SA reported annual total liabilities of 36.3 Million EUR in 2021, up 3.46% from previous year.
Celyad Oncology SA reported quarterly total liabilities of 26.6 Million EUR for 2023 FY, up 72.8% from previous quarter.
Celyad Oncology SA reported quarterly total liabilities of 9.97 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Celyad Oncology SA (2023 - 2011)

Historical Annual Total Liabilities of Celyad Oncology SA (2023 - 2011)

Year	Total Liabilities	Total Liabilities Growth
2023	9.97 Million EUR	-35.2%
2022	15.39 Million EUR	-57.58%
2021	36.3 Million EUR	3.46%
2020	35.09 Million EUR	-20.64%
2019	44.21 Million EUR	14.23%
2018	38.71 Million EUR	28.64%
2017	30.09 Million EUR	-37.21%
2016	47.92 Million EUR	-0.27%
2015	48.05 Million EUR	177.89%
2014	17.29 Million EUR	11.65%
2013	15.48 Million EUR	2.85%
2012	15.05 Million EUR	149.42%
2011	6.03 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	9.58 Million EUR	0.0%
2023 FY	26.6 Million EUR	72.8%
2023 Q4	9.97 Million EUR	0.0%
2023 Q2	11.15 Million EUR	0.0%
2022 Q1	32.72 Million EUR	-9.86%
2022 Q4	32.03 Million EUR	0.0%
2022 FY	15.39 Million EUR	-57.58%
2022 Q2	32.49 Million EUR	-0.72%
2021 Q4	36.3 Million EUR	-7.28%
2021 Q2	37.82 Million EUR	2.84%
2021 Q1	36.78 Million EUR	4.82%
2021 FY	36.3 Million EUR	3.46%
2021 Q3	39.15 Million EUR	3.51%
2020 Q4	35.09 Million EUR	0.0%
2020 Q2	45.44 Million EUR	0.0%
2020 FY	35.09 Million EUR	-20.64%
2019 Q4	44.21 Million EUR	0.0%
2019 Q2	40.43 Million EUR	0.0%
2019 FY	44.21 Million EUR	14.23%
2018 Q4	38.71 Million EUR	0.0%
2018 FY	38.71 Million EUR	28.64%
2018 Q2	36.37 Million EUR	0.0%
2017 FY	30.09 Million EUR	-37.21%
2017 Q2	43.04 Million EUR	0.0%
2017 Q4	30.09 Million EUR	0.0%
2016 FY	47.92 Million EUR	-0.27%
2016 Q4	47.92 Million EUR	0.0%
2016 Q2	43.36 Million EUR	0.0%
2015 FY	48.05 Million EUR	177.89%
2015 Q2	58.4 Million EUR	0.0%
2015 Q4	48.05 Million EUR	0.0%
2014 FY	17.29 Million EUR	11.65%
2014 Q2	16.12 Million EUR	0.0%
2014 Q4	17.29 Million EUR	0.0%
2013 Q4	15.48 Million EUR	0.0%
2013 Q2	16.16 Million EUR	0.0%
2013 FY	15.48 Million EUR	2.85%
2012 Q4	15.05 Million EUR	0.0%
2012 FY	15.05 Million EUR	149.42%
2011 FY	6.03 Million EUR	0.0%

Peer Total Liabilities Comparison of Celyad Oncology SA

Name	Total Liabilities	Total Liabilities Difference
Nicox S.A.	31.56 Million EUR	68.391%
European Medical Solutions	33.86 Million EUR	70.537%
FERMENTALG	19.39 Million EUR	48.562%
argenx SE	402.79 Million EUR	97.523%
BioSenic S.A.	32.26 Million EUR	69.074%
Hyloris Pharmaceuticals SA	8.61 Million EUR	-15.862%
Onward Medical N.V.	25.69 Million EUR	61.172%
Oxurion NV	19.73 Million EUR	49.443%
PHAXIAM Therapeutics S.A.	25.69 Million EUR	61.168%
Financière de Tubize SA	123.65 Million EUR	91.93%
UCB SA	6.56 Billion EUR	99.848%